ARch Biopartners Inc (ACHFF)
1.03 ? 0.0235 (2.33%)
Volume: 10,303 @08/14/20 3:07:34 PM EDT
Bid Ask Day's Range
0.98 1.04 1.03 - 1.0335
ACHFF Detailed Quote
1.03 ? 0.0235 (2.33%)
Volume: 10,303 @08/14/20 3:07:34 PM EDT
Bid Ask Day's Range
0.98 1.04 1.03 - 1.0335
ACHFF Detailed Quote
Recent ACHFF News
- Arch Biopartners Closes Non-Brokered Private Placement • GlobeNewswire Inc. • 04/02/2026 09:45:00 AM
- Arch Biopartners Arranges Non-Brokered Private Placement • GlobeNewswire Inc. • 03/30/2026 10:03:00 AM
- Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial • GlobeNewswire Inc. • 03/24/2026 01:13:43 PM
- Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide • GlobeNewswire Inc. • 03/20/2026 11:05:00 AM
- Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease • GlobeNewswire Inc. • 02/09/2026 12:28:52 PM
- Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board • GlobeNewswire Inc. • 01/16/2026 01:15:00 PM
- Arch Biopartners Announces Ethics Approval for St. Michael’s Hospital to Participate in the Phase II Cardiac Surgery-Associated AKI Trial for LSALT Peptide • GlobeNewswire Inc. • 12/16/2025 12:40:00 PM
- Arch Biopartners Closes Non-Brokered Private Placement • GlobeNewswire Inc. • 11/19/2025 09:27:50 PM
- Arch Biopartners Arranges Non-Brokered Private Placement • GlobeNewswire Inc. • 11/10/2025 01:10:00 PM
- Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia • GlobeNewswire Inc. • 11/05/2025 01:30:00 PM
- Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD) • GlobeNewswire Inc. • 09/17/2025 11:15:00 AM
